192 related articles for article (PubMed ID: 28521777)
1. CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin.
Gao F; Xu T; Wang X; Zhong S; Chen S; Zhang M; Zhang X; Shen Y; Wang X; Xu C; Shen Z
J Exp Clin Cancer Res; 2017 May; 36(1):70. PubMed ID: 28521777
[TBL] [Abstract][Full Text] [Related]
2. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CIP2A promotes bladder cancer progression by regulating EMT.
Pang X; Fu X; Chen S; Zhu X; Qi H; Li Y; Li F; Tan W
Clin Transl Oncol; 2016 Mar; 18(3):289-95. PubMed ID: 26243398
[TBL] [Abstract][Full Text] [Related]
4. CIP2A protein expression in high-grade, high-stage bladder cancer.
Huang LP; Savoly D; Sidi AA; Adelson ME; Mordechai E; Trama JP
Cancer Med; 2012 Aug; 1(1):76-81. PubMed ID: 23342256
[TBL] [Abstract][Full Text] [Related]
5. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
6. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
[TBL] [Abstract][Full Text] [Related]
7. CIP2A regulates proliferation and apoptosis of multiple myeloma cells.
Zheng Z; Qiao Z; Chen W; Gong R; Wang Y; Xu L; Ma Y; Zhang L; Lu Y; Jiang B; Li G; Dong C
Mol Med Rep; 2016 Sep; 14(3):2705-9. PubMed ID: 27484817
[TBL] [Abstract][Full Text] [Related]
8. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
[TBL] [Abstract][Full Text] [Related]
9. High-glucose promotes proliferation of human bladder cancer T24 cells by activating Wnt/β-catenin signaling pathway.
Gao L; Xu FM; Shi WJ; Zhang S; Lu YL; Zhao DK; Long YF; Teng RB; Ge B
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8151-8160. PubMed ID: 30556853
[TBL] [Abstract][Full Text] [Related]
10. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF
Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514
[TBL] [Abstract][Full Text] [Related]
11. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
12. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
13. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.
Peng B; Lei N; Chai Y; Chan EK; Zhang JY
Mol Biosyst; 2015 Jan; 11(1):105-14. PubMed ID: 25325377
[TBL] [Abstract][Full Text] [Related]
14. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.
Li W; Ge Z; Liu C; Liu Z; Björkholm M; Jia J; Xu D
Clin Cancer Res; 2008 Jun; 14(12):3722-8. PubMed ID: 18559589
[TBL] [Abstract][Full Text] [Related]
15. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.
Xue Y; Wu G; Wang X; Zou X; Zhang G; Xiao R; Yuan Y; Long D; Yang J; Wu Y; Xu H; Liu F; Liu M
Med Oncol; 2013 Mar; 30(1):406. PubMed ID: 23275123
[TBL] [Abstract][Full Text] [Related]
16. CIP2A is associated with human breast cancer aggressivity.
Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
[TBL] [Abstract][Full Text] [Related]
17. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
[TBL] [Abstract][Full Text] [Related]
18. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
19. Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.
Pallai R; Bhaskar A; Barnett-Bernodat N; Gallo-Ebert C; Nickels JT; Rice LM
Tumour Biol; 2015 Aug; 36(8):6067-74. PubMed ID: 25736928
[TBL] [Abstract][Full Text] [Related]
20. Suppression of LETM1 by siRNA inhibits cell proliferation and invasion of bladder cancer cells.
Huang B; Zhang J; Zhang X; Huang C; Hu G; Li S; Xie T; Liu M; Xu Y
Oncol Rep; 2017 Nov; 38(5):2935-2940. PubMed ID: 29048663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
